title: Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control.
abstract: BACKGROUND
  There has been increasing interest in the use of medications that affect the dopamine receptor in the treatment of alcoholism. Aripiprazole has the unique pharmacology of being a partial dopamine agonist serving to stabilize brain dopamine systems in both frontal cortical and subcortical areas. As such, it might act to dampen alcohol reinforcement and craving and/or alter control over alcohol use. The current clinical laboratory study was conducted to evaluate the safety and efficacy of aripiprazole as a potential agent to alter drinking and objective effects of alcohol.
  
  
  METHODS
  Thirty nontreatment seeking alcoholics were enrolled in a subacute human laboratory study and received double-blind treatment with up to 15 mg of aripiprazole (n = 15) or identical placebo (n = 15) for 8 days. Tolerability and utility of aripiprazole was monitored during natural drinking over the first 6 days of medication treatment and also during a free choice limited access alcohol consumption paradigm following an initial drink of alcohol in a bar-lab setting on Day 8.
  
  
  RESULTS
  Aripiprazole was well tolerated and reduced drinking in nontreatment seeking alcoholics over 6 days of natural drinking--especially in those with lower self control (more impulsive). It also reduced drinks in the bar-lab after a priming drink and broke the link between priming drink induced stimulation and further drinking. During the bar-lab drinking session, there were no differences in subjective high, intoxication, or craving between subjects treated with aripiprazole or placebo.
  
  
  CONCLUSIONS
  This study joins several others in demonstrating the utility of subacute dosing laboratory paradigms for evaluating medication effects in alcoholics. Aripiprazole was well tolerated and lowered alcohol use, especially in those with lower impulse control. Further study is needed to determine the safety and utility of aripiprazole in the treatment of alcoholism and if subgroups of alcoholics are more likely to respond.
authors.affiliation: Alcohol Research Center, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina 29425, USA. voronin@musc.edu
authors.forename: Konstantin
authors.initials: K
authors.lastname: Voronin
authors.forename: Patrick
authors.initials: P
authors.lastname: Randall
authors.forename: Hugh
authors.initials: H
authors.lastname: Myrick
authors.forename: Raymond
authors.initials: R
authors.lastname: Anton
mesh_terms: D000328:Adult; D000339:Affect / Q000187:drug effects; D000428:Alcohol Drinking / Q000188:drug therapy* / Q000523:psychology; D000437:Alcoholism / Q000188:drug therapy / Q000523:psychology; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000068180:Aripiprazole; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007175:Impulsive Behavior / Q000188:drug therapy / Q000523:psychology; D008297:Male; D008962:Models, Theoretical; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D015363:Quinolones / Q000494:pharmacology / Q000627:therapeutic use*; D012890:Sleep / Q000187:drug effects; D012927:Social Control, Informal
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole
references.citation: Clin Ther. 2004 May;26(5):649-66
references.pmid: 15220010
references.citation: Schizophr Res. 2003 Jun 1;61(2-3):123-36
references.pmid: 12729864
references.citation: Am J Public Health. 1996 Jul;86(7):966-72
references.pmid: 8669520
references.citation: Psychopharmacology (Berl). 2004 Apr;173(1-2):32-40
references.pmid: 14722705
references.citation: J Clin Psychiatry. 2006 Apr;67(4):626-37
references.pmid: 16669728
references.citation: Neuropsychopharmacology. 2003 Apr;28(4):755-64
references.pmid: 12655322
references.citation: Arch Gen Psychiatry. 1984 Sep;41(9):879-84
references.pmid: 6466047
references.citation: Alcohol Clin Exp Res. 1999 Nov;23(11):1751-60
references.pmid: 10591591
references.citation: Alcohol Clin Exp Res. 1995 Jun;19(3):600-6
references.pmid: 7573780
references.citation: Biol Psychiatry. 2007 Mar 1;61(5):582-90
references.pmid: 16806092
references.citation: Psychopharmacology (Berl). 2002 Feb;160(1):19-29
references.pmid: 11862370
references.citation: Eur J Pharmacol. 2004 Jun 16;493(1-3):75-83
references.pmid: 15189766
references.citation: J Abnorm Psychol. 1982 Jun;91(3):199-209
references.pmid: 7096790
references.citation: Alcohol Clin Exp Res. 1993 Feb;17(1):140-6
references.pmid: 8452195
references.citation: Alcohol Clin Exp Res. 2003 Dec;27(12):1892-900
references.pmid: 14691376
references.citation: Schizophr Bull. 2005 Jul;31(3):672-96
references.pmid: 16020551
references.citation: Psychopharmacology (Berl). 2000 Sep;151(4):321-7
references.pmid: 11026738
references.citation: J Stud Alcohol. 2000 Mar;61(2):220-4
references.pmid: 10757131
references.citation: Biol Psychiatry. 2005 Jun 1;57(11):1263-72
references.pmid: 15949998
references.citation: J Clin Psychopharmacol. 2005 Aug;25(4):363-6
references.pmid: 16012280
references.citation: Alcohol Clin Exp Res. 1987 Jun;11(3):269-73
references.pmid: 3307492
references.citation: Arch Gen Psychiatry. 2003 Jul;60(7):727-35
references.pmid: 12860777
references.citation: Neuropsychopharmacology. 1999 Jun;20(6):612-27
references.pmid: 10327430
references.citation: Alcohol Alcohol. 2006 Jul-Aug;41(4):391-8
references.pmid: 16684847
references.citation: Alcohol Clin Exp Res. 2006 Sep;30(9):1451-65
references.pmid: 16930207
references.citation: Alcohol Res Health. 2003;27(2):146-52
references.pmid: 15303625
references.citation: Can J Psychiatry. 2005 Mar;50(4):244
references.pmid: 15898470
references.citation: Nat Neurosci. 2005 Nov;8(11):1458-63
references.pmid: 16251988
references.citation: Br J Addict. 1989 Nov;84(11):1353-7
references.pmid: 2597811
references.citation: Am J Addict. 2003;12(s1):s53-s68
references.pmid: 14972780
references.citation: Arch Gen Psychiatry. 1996 Mar;53(3):225-31
references.pmid: 8611059
references.citation: J Clin Psychol. 1995 Nov;51(6):768-74
references.pmid: 8778124
references.citation: Neuropsychopharmacology. 2001 Feb;24(2):97-129
references.pmid: 11120394
references.citation: Alcohol Clin Exp Res. 2004 Sep;28(9):1362-70
references.pmid: 15365307
references.citation: J Neurosci. 1998 Dec 15;18(24):10663-71
references.pmid: 9852601
references.citation: Neuropsychopharmacology. 2004 Feb;29(2):393-402
references.pmid: 14679386
references.citation: Neurosci Res. 2004 Sep;50(1):1-11
references.pmid: 15288493
references.citation: Alcohol Clin Exp Res. 2008 Apr;32(4):573-9
references.pmid: 18261195
references.citation: J Clin Psychopharmacol. 2005 Aug;25(4):349-57
references.pmid: 16012278
references.citation: Alcohol Clin Exp Res. 1996 Oct;20(7 Suppl):3A-9A
references.pmid: 8904988
references.citation: Neuropsychopharmacology. 2005 Nov;30(11):2103-14
references.pmid: 15988473
references.citation: J Clin Psychopharmacol. 2008 Feb;28(1):5-12
references.pmid: 18204334
references.citation: Exp Clin Psychopharmacol. 2000 May;8(2):225-49
references.pmid: 10843306
references.citation: J Neurosci. 2002 May 1;22(9):3332-7
references.pmid: 11978808
references.citation: Am J Psychiatry. 1999 Nov;156(11):1758-64
references.pmid: 10553740
references.citation: J Pharmacol Exp Ther. 2002 Jul;302(1):381-9
references.pmid: 12065741
references.citation: Arch Gen Psychiatry. 2008 Apr;65(4):466-75
references.pmid: 18391135
references.citation: Psychopharmacology (Berl). 2004 Sep;175(3):296-302
references.pmid: 15127179
references.citation: Brain Res Bull. 2006 Apr 14;69(3):259-65
references.pmid: 16564420